Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

Canada NewsWire September 28, 2019

ESSA to Present at Ladenburg Thalmann Healthcare Conference

Canada NewsWire September 19, 2019

ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

Canada NewsWire September 5, 2019

ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million

Canada NewsWire August 27, 2019

ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

Canada NewsWire August 23, 2019

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

PR Newswire August 14, 2019

ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective

Canada NewsWire July 31, 2019

ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics

Canada NewsWire July 30, 2019

ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer

Canada NewsWire July 15, 2019

ESSA Provides Update on Court Hearing

Canada NewsWire July 8, 2019

ESSA Provides an Update to the Acquisition of Realm Therapeutics

Canada NewsWire June 26, 2019

ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders

Canada NewsWire June 25, 2019

ESSA Pharma to Hold Annual Shareholders' Meeting and Announces Three Realm-Nominated Directors

Canada NewsWire June 21, 2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Realm Therapeutics plc to ESSA Pharma Inc., LLC is Fair to Shareholders

GlobeNewswire May 20, 2019

Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

Canada NewsWire May 16, 2019

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019

Canada NewsWire May 10, 2019

Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting

Canada NewsWire May 4, 2019

ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019

Canada NewsWire April 25, 2019

ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting

Canada NewsWire April 17, 2019

ESSA Pharma Grants Stock Options

PR Newswire April 12, 2019